

To NASDAQ OMX Copenhagen A/S  
Translation

Company release No. 15/2009

## Nine-month interim report (Q3) 2009 (unaudited)

### Financial performance in the nine months ended September 30, 2009

*(Comparative figures for the same period last year are shown in brackets)*

- ▶ Sales growth continued in Q3 and organic growth in vaccine sales was 10%
- ▶ Revenue for the first nine months of the year was DKK 1,393 million (1,308)
- ▶ Capacity costs increased by 1% to DKK 875 million (869)
- ▶ Operating profit (EBIT) for the first nine months of the year rose 50% to DKK 117 million (78)
- ▶ Operating profit before depreciation and amortization (EBITDA) was DKK 176 million (139)
- ▶ Profit for the period was DKK 82 million (63)

### Adjustment of 2009 financial outlook

For the 2009 financial year, ALK forecasts organic growth in allergy vaccine sales of approximately 10%. Operating profit (EBIT) is forecast at a minimum of DKK 150 million. Operating profit before depreciation and amortization (EBITDA) is forecast at a minimum of DKK 230 million.

Hørsholm, November 19, 2009

**ALK-Abelló A/S**

#### Contact:

Jens Bager, President and CEO, tel +45 4574 7576.

*ALK will host a conference call for analysts and investors today at 3.30 p.m. (CET) at which Jens Bager, President and CEO, and Jutta of Rosenborg, CFO, will review the results. Danish participants should call in on tel +45 7026 5040 before 3.25 p.m. (CET), and international participants should call in on tel +44 208 817 9301 before 3.25 p.m. (CET). The conference call will also be webcast on our website: [www.alk-abello.com](http://www.alk-abello.com), where the related presentation will be available shortly before the conference call begins.*

## FINANCIAL HIGHLIGHTS AND KEY RATIOS (unaudited)

Amounts in DKKm	9M 2009	9M 2008	Full year 2008
<b>Income statement</b>			
Revenue	1,393	1,308	1,784
Operating profit before other operating income and expenses	90	53	94
Operating profit (EBIT)	117	78	119
Net financial items	15	28	38
Profit before tax (EBT)	132	106	157
Net profit	82	63	95
Operating profit before depreciations and amortization (EBITDA)	176	139	205
Average number of employees	1,503	1,445	1,454
<b>Statement of financial position</b>			
Total assets	2,578	2,573	2,538
Invested capital	1,452	1,268	1,367
Equity	1,882	1,861	1,862
<b>Cash flow and investments</b>			
Depreciations, amortization and impairment	59	61	86
Cash flow from operating activities	136	79	189
Cash flow from investing activities	(159)	(250)	(397)
- of which investment in tangible assets	(120)	(245)	(364)
Free cash flow	(23)	(171)	(208)
<b>Information on shares</b>			
Share capital	101	101	101
Shares in thousands of DKK 10 each	10,128	10,128	10,128
Share price – DKK	474	549	520
Net asset value per share – DKK	186	184	184
<b>Key figures</b>			
Gross margin – %	69.3	70.5	70.5
EBIT margin – %	8.4	6.0	6.7
Earnings per share (EPS) – DKK	8.2	6.3	9.5
Diluted earnings per share (DEPS) – DKK	8.2	6.3	9.5
Cash flow per share (CFPS) – DKK	13.7	7.9	18.9
Share price/Net asset value	2.6	3.0	2.8

Definitions: see last page

## INCOME STATEMENT

Q3 2008		Q3 2009		Amounts in DKKm	9M 2009		9M 2008	
	%		%			%		%
437	100	466	100	<b>Revenue</b>	1,393	100	1,308	100
133	30	142	30	Cost of sales	428	31	386	30
304	70	324	70	<b>Gross profit</b>	965	69	922	70
81	19	82	18	Research and development expenses	244	18	246	19
190	43	205	44	Sales, marketing and administrative expenses	631	45	623	48
-	-	9	2	Other operating income and expenses	27	2	25	2
33	8	46	10	<b>Operating profit (EBIT)</b>	117	8	78	6
10	2	1	0	Financial income	18	1	30	2
(15)	(3)	2	0	Financial expenses	3	0	2	0
58	13	45	10	<b>Profit before tax (EBT)</b>	132	9	106	8
23	5	17	4	Tax on profit	50	4	43	3
35	8	28	6	<b>Net profit</b>	82	6	63	5
53	12	66	14	<b>Operating profit before depreciations and amortization (EBITDA)</b>	176	13	139	11

## FINANCIAL REVIEW

(Growth rates for revenue are stated as organic growth)


**Revenue** for Q3 grew as expected. Thus, revenue for the first nine months of the year increased by 7% to DKK 1,393 million (1,308). The impact from exchange rates was negative by one percentage point, primarily as a consequence of the development in the GBP/DKK exchange rate. Reference is made to note 2 to the financial statements for details on sales performance and exchange rate effects.

The company's core business, allergy vaccine sales, continued to grow in Q3. The rate of growth in vaccine sales for the first nine months of the year was 10%, which was in line with expectations.

## Revenue – product lines

Sales of injection-based allergy vaccines (SCIT) grew by 8% to DKK 666 million (611) in the first nine months of 2009. The sales growth was broadly based, driven by the North and Central European Regions as well as North America and China. Sales

of injection-based vaccines accounted for 48% (47) of total sales.




Sales of sublingual, drop-based vaccines (SLIT droplets) grew by 6% to DKK 401 million (380). Sales performance was satisfactory in France and Spain, while sales dropped in Italy as a consequence of the economic downturn. ALK recorded declining sales in the Central European Region as a consequence of general market

developments. The Dutch regulatory authorities have decided to discontinue the reimbursement for unregistered allergy vaccines, which causes a general downturn in the Dutch market. Overall, sales of drop-based SLIT products still accounted for 29% (29) of total sales.

Sales of GRAZAX<sup>®</sup>, the tablet-based allergy vaccine, continued to show satisfactory growth and increased by 53% to DKK 94 million (63). Growth in tablet sales was especially generated in the North and Central European Regions. Tablet sales account for 7% (5) of the company's total sales, which makes GRAZAX<sup>®</sup> the product currently making the greatest contributions to the growth in ALK's sales.

As expected, sales of other products fell by 5% to DKK 232 million (254). This was in particular the result of a well-known variation in the sale of adrenaline products. Compared to 2008, fewer adrenaline pens expire in 2009 and thus have to be renewed. When this variation is taken into account, the underlying growth in adrenaline sales in Q3 was satisfactory.



**Revenue – markets**

Sales in the Northern European Region totalled DKK 294 million (315) equivalent to a growth rate of 0%, taking into account the exchange rate effect. As mentioned previously, performance was adversely affected by the variation in adrenaline sales and by the consequences of the changes in the Dutch reimbursement system.

Sales in the Central European Region grew by 9% to DKK 563 million (515) as a result of continued

growth in tablet sales and sales of injection-based vaccines.

In the Southern European Region, sales also increased, namely by 9% to DKK 382 million (351). France and Spain were the main contributors to the increase. In Italy and still more and more in Spain, the overall allergy vaccine market is under strong pressure as a result of the economic downturn. Although partial reimbursement is available in these countries, patients' own payment makes up a substantial part of the cost of treatment, which affects patients' incentive to begin allergy vaccination.

Revenue from other markets grew by 10% to DKK 154 million (127). In particular, sales of injection-based products in North America and China were the main contributors to this performance.

**Cost of sales** amounted to DKK 428 million (386), and gross profit increased by 5% to DKK 965 million (922). The reported gross margin was 69% (70) and was adversely affected, among other things, by developments in exchange rates and increasing procurement prices of ALK's trade goods including adrenaline pens. In Q3, the impact from exchange rates was declining compared to the first half of the year due to the falling USD/DKK exchange rate. ALK still expects that the gross margin for the full year will be on a level with 2008.

ALK continues to show general cost restraint. Total **capacity costs** increased by 1% to DKK 875 million (869). Research and development costs totalled DKK 244 million (246), equivalent to 18% of revenue. The costs primarily related to the continuing development of the tablet-based vaccines, including support for the collaboration with Schering-Plough, the company's US-based collaborative partner. Sales, marketing and administrative expenses were DKK 631 million (623).

The underlying operating performance remained satisfactory. **Operating profit** before depreciation and amortization (EBITDA) was DKK 176 million (139). Reported operating profit (EBIT) increased by 50% to DKK 117 million (78), corresponding to an EBIT margin of 8%. Exchange rates had an

adverse impact on EBIT. EBIT included net operating income of DKK 25 million from Schering-Plough. The payment related to the pharmaceutical development activities concerning the new tablet-based vaccine against ragweed allergy. For the full year 2009, the aggregate payment will be DKK 33 million.

**Net financials** was an income of DKK 15 million (28) and consisted of net interest income as well as realized and unrealized exchange gains on intercompany balances in and holdings of foreign currency.

**Income tax** for the period amounted to DKK 50 million (43), corresponding to an effective tax rate of 38%. Profit for the period was DKK 82 million (63).

**The cash flow** from operating activities showed a satisfactory trend and was an inflow of DKK 136 million (an inflow of 79). The cash flow was affected by changes in working capital and a subsequent adjustment to an instalment of corporate income tax paid on account. The cash flow from investing activities was an outflow of DKK 159 million (an outflow of 250) which related to planned investments in buildings and production facilities and ongoing maintenance. The free cash flow for the period was an outflow of DKK 23 million (an outflow of 171). The cash flow from financing activities was an outflow of DKK 59 million (an outflow of 337) and primarily related to the distribution of ordinary dividends of DKK 50 million in respect of the 2008 financial year. At the end of the quarter, cash totalled DKK 366 million (525).

#### **Adjustment of 2009 financial outlook**

For the 2009 financial year, ALK forecasts organic growth in allergy vaccine sales of approximately 10% against the previous forecast of 10% or more.

Also, ALK continues to expect a gross margin at the 2008 level, moderate growth in capacity costs and a payment from Schering-Plough of DKK 33 million. Against this background, EBIT is expected to be a minimum of DKK 150 million against the previous forecast of a minimum of DKK 140 million. The EBITDA forecast is retained at a minimum of DKK 230 million. Accordingly, it is expected that the consolidated profit will increase again in 2009.

## **OPERATING REVIEW**

### **GRAZAX<sup>®</sup>**

In September, the health authorities in 27 European countries approved GRAZAX<sup>®</sup> as a disease-modifying allergy treatment, making the product the only approved tablet-based treatment against grass pollen allergy with a documented sustained effect. The approval was based on the results from the first follow-up year of a long-term study (GT-08) of GRAZAX<sup>®</sup> which were published at the European allergy conference in June. The results document that the significant improvement of patients' eye and nose symptoms and quality of life persists after completion of the recommended three-year treatment regimen.

The regulatory approval marks the provisional culmination of ALK's research and development activities within tablet-based allergy immunotherapy. The development programme has demonstrated robust scientific results which support ALK's ambition of improving the quality of allergy treatment and expanding the use of allergy immunotherapy.

Treatment of adult patients with GRAZAX<sup>®</sup> is currently available with reimbursement in 13 European countries. In addition to the five countries in which GRAZAX<sup>®</sup> is currently available for children and adolescents, the regulatory authorities in Finland, Italy and Norway have resolved to provide reimbursement for this important patient population. These commitments will ensure launch well before the 2010 pollen season.

In mid-November, ALK announced the start-up of a major clinical study called *GRAZAX<sup>®</sup> Asthma Prevention*, or the GAP study. The study is the largest ever of its kind and is designed to investigate the potential of the grass tablet in preventing the development of asthma and new allergies in children and adolescents. Studies of allergic children have shown that they have up to seven times greater risk of developing asthma later in life. The GAP study will run over five years in Europe and will include 600 children aged 5-12.

ALK's US partner, Schering-Plough, announced in early November that GRAZAX<sup>®</sup> has successfully met its primary endpoint in a US Phase III clinical study in adults diagnosed with grass pollen allergy. The study included 439 adult patients who were randomized to receive either placebo or GRAZAX<sup>®</sup>. Additionally, the adverse events experienced by patients receiving the grass tablet in the study were similar to previous studies in adults and include oral itching. These data are planned to be submitted at a medical conference to be held in the USA in 2010. The purpose of the study is to form the basis for a later application with the US health authorities for selling and marketing the product in North America.

#### **Merck acquires Schering-Plough**

The collaboration with Schering-Plough remains satisfactory and is proceeding according to plan. On November 3, Schering-Plough was merged with the pharmaceutical company Merck, with the latter as the continuing company under the name of Merck.

#### **New injection-based vaccine in Germany**

ALK has introduced a new injection-based product in Germany, aiming to continue to strengthen its product range and market position in Germany. The new product, AVANZ<sup>®</sup>, builds on ALK's conventional vaccines and is more convenient to patients, partly because it allows for a significantly faster up dosing. The product is initially being marketed on an individual patient basis, but it is subject to a German statutory requirement of registration of all major allergy vaccines. It is expected that AVANZ<sup>®</sup> will be registered within the coming years.

#### **Acquisition of German distributor**

ALK has signed an agreement to acquire the activities of ThemoCare Allergiedienst, a small allergy operator in Germany. This formerly privately owned company has been a distributor of ALK's French products on the German market since 1999. The acquisition strengthens ALK's market position and geographical presence in certain parts of Germany. The effective date of the acquisition was October 1, 2009, and it does not change the outlook for sales and earnings.

#### **New diagnostic product in the USA**

ALK has acquired the rights to introduce a diagnostic product, PRE-PEN<sup>®</sup>, in the USA. This product allows physicians to efficiently test whether a patient is allergic to penicillin. PRE-PEN<sup>®</sup> is produced by the company AllerQuest and was approved by the US health authorities in September 2009. The launch of the product does not change the outlook for sales and earnings.

#### **Changes to Dutch reimbursement schemes**

The Dutch regulatory authorities have decided to adjust the reimbursement schemes for allergy vaccines effective October 1, to the effect that in future only registered vaccine products will be eligible for reimbursement. Patients already in treatment with unregistered vaccines will receive reimbursement to complete their therapy, whereas new patients will only be eligible for reimbursement for registered alternatives, such as GRAZAX<sup>®</sup>. This decision will have an adverse effect on ALK's current sales as its drop-based SLIT products are not registered in the Netherlands. ALK's sales of the affected products totalled approximately DKK 50 million in 2008, and are expected to gradually disappear over the next few years.

The discontinuation of reimbursement for unregistered vaccines has caused a general and substantial adverse trend in the Dutch market.

#### **Regulatory changes**

For many years, certain allergy vaccines have been supplied on a "named patient" (NP) or individual patient basis in a number of European countries. This means that the products are not registered pharmaceuticals, but that they are used under the responsibility of the prescribing physician and produced and supplied directly to a named patient. More than 15 different allergy companies, including ALK, market NP products, which especially include drop-based allergy vaccines, which are more widely used in southern and central Europe.

The healthcare authorities in a number of countries have worked on modernizing their rules for the NP products for a number of years in order to ensure the highest possible quality and documentation in treatment. It is primarily the regulatory authorities in Germany, the Netherlands, Spain and Italy who

have initiated the updating of the rules. In France, the authorities established a new system for approving NP products already in 2004/05.

ALK continues to believe that, overall, setting high regulatory standards will benefit patients and the industry as a whole.

### **Risk factors**

This interim report contains forward-looking statements, including forecasts of future revenue and operating profit as well as expected business-related events. Such statements are subject to risks and uncertainties as various factors, some of which are beyond the control of the ALK Group, may cause actual results and performance to differ materially from the forecasts made in this interim report. Without being exhaustive, such factors include, among others, general economic and business conditions, including legal issues, uncertainty relating to pricing, reimbursement rules

and market penetration for GRAZAX<sup>®</sup>, fluctuations in currencies and demand, changes in competitive factors and reliance on suppliers, but also factors such as side effects from the use of the company's existing and future products since allergy vaccination may be associated with allergic reactions of differing extent, duration and severity. Moreover, ALK cannot rule out that a general economic downturn could have an adverse impact on the use of allergy vaccines.

*This interim report has been translated from Danish into English. However, the Danish text is the governing text for all purposes, and if there is any discrepancy, the Danish wording is applicable.*

### **Financial calendar**

Silent period	January 26, 2010
Annual report 2009	February 23, 2010

## STATEMENT BY THE MANAGEMENT

The Board of Directors and Board of Management today considered and approved the interim report of ALK-Abelló A/S for the period January 1 – September 30, 2009.

This interim report has been prepared in accordance with IAS “Interim Financial Reporting” as adopted by the EU and additional Danish disclosure requirements for the interim reports of listed companies. As in previous years, the interim report is unaudited.

In our opinion, the interim report gives a true and fair view of the Group’s assets, equity and liabilities, financial position, results of operations and consolidated cash flows for the period January 1 – September 30, 2009. Moreover, in our opinion, the interim report gives a true and fair view of developments in the Group’s activities and financial position and describes significant risk and uncertainty factors that may affect the Group.

Hørsholm, November 19, 2009

### Board of Management

Jens Bager  
(President and CEO)

Jørgen Damsbo Andersen

Henrik Jacobi

Flemming Steen Jensen

Jutta of Rosenberg

### Board of Directors

Jørgen Worning  
(Chairman)

Thorleif Krarup  
(Vice Chairman)

Nils Axelsen

Jesper Fromberg Nielsen

Anders Gersel Pedersen

Brian Petersen

Ingelise Saunders

Lars Simonsen

Peter Adler Würtzen



## INCOME STATEMENT (unaudited)

ALK Group			ALK Group	
Q3 2008	Q3 2009	Note	9M 2009	9M 2008
Amounts in DKKm				
437	466	2	1,393	1,308
133	142		428	386
304	324		965	922
81	82		244	246
148	159		498	488
42	46		133	135
1	9	3	28	31
1	-	3	1	6
33	46		117	78
10	1		18	30
(15)	2		3	2
58	45		132	106
23	17		50	43
35	28		82	63
3.5	2.8		8.2	6.3
3.5	2.8		8.2	6.3

## STATEMENT OF COMPREHENSIVE INCOME (unaudited)

ALK Group			ALK Group	
Q3 2008	Q3 2009		9M 2009	9M 2008
Amounts in DKKm				
35	28		82	63
10	(12)		(17)	3
4	2		(1)	7
1	-		-	-
15	(10)		(18)	10
50	18		64	73

## CASH FLOW STATEMENT (unaudited)

	ALK Group	
	9M 2009	9M 2008
Amounts in DKKm		
<b>Net profit</b>	<b>82</b>	<b>63</b>
Adjustments:		
Tax on profit	50	43
Financial income and expenses	(15)	(28)
Share-based payments	6	6
Depreciations, amortization and impairment	59	61
Change in provisions	2	2
Net financial items, paid	6	25
Income taxes, paid	(22)	(62)
<b>Cash flow before change in working capital</b>	<b>168</b>	<b>110</b>
Change in inventories	(2)	-
Change in receivables	(34)	(18)
Change in short-term payables	4	(13)
<b>Cash flow from operating activities</b>	<b>136</b>	<b>79</b>
Additions, intangible assets	(21)	(5)
Additions, tangible assets	(120)	(245)
Change in other financial assets	(18)	-
<b>Cash flow from investing activities</b>	<b>(159)</b>	<b>(250)</b>
<b>Free cash flow</b>	<b>(23)</b>	<b>(171)</b>
Dividend paid to shareholders of the parent	(50)	(330)
Change in financial liabilities	(9)	(7)
<b>Cash flow from financing activities</b>	<b>(59)</b>	<b>(337)</b>
<b>Net cash flow</b>	<b>(82)</b>	<b>(508)</b>
Cash and cash equivalents at January 1	449	1,030
Unrealized gain/(loss) on foreign currency carried as cash and cash equivalents	(1)	3
Net cash flow	(82)	(508)
<b>Cash and cash equivalents at September 30</b>	<b>366</b>	<b>525</b>

The cash flow statement has been adjusted to the effect that exchange rate adjustments in foreign subsidiaries are not included in the statement. As a result, the individual figures in the cash flow statement cannot be reconciled directly to the income statement and balance sheet.

## BALANCE SHEET (unaudited)

Assets	ALK Group		
	Sept. 30, 2009	Dec. 31, 2008	Sept. 30, 2008
Amounts in DKKm			
<b>Non-current assets</b>			
<b>Intangible assets</b>			
Goodwill	365	364	376
Other intangible assets	58	50	34
	<b>423</b>	<b>414</b>	<b>410</b>
<b>Tangible assets</b>			
Land and buildings	286	300	302
Plant and machinery	125	128	127
Other fixtures and equipment	59	61	62
Property, plant and equipment in progress	574	487	370
	<b>1,044</b>	<b>976</b>	<b>861</b>
<b>Other non-current assets</b>			
Securities and receivables	22	4	6
Deferred tax assets	88	91	128
	<b>110</b>	<b>95</b>	<b>134</b>
<b>Total non-current assets</b>	<b>1,577</b>	<b>1,485</b>	<b>1,405</b>
<b>Current assets</b>			
Inventories	293	292	282
Trade receivables	234	188	227
Receivables from affiliates	28	28	25
Income tax receivables	40	43	57
Other receivables	14	31	24
Prepayments	26	22	28
Cash and cash equivalents	366	449	525
<b>Total current assets</b>	<b>1,001</b>	<b>1,053</b>	<b>1,168</b>
<b>Total assets</b>	<b>2,578</b>	<b>2,538</b>	<b>2,573</b>

## BALANCE SHEET (unaudited)

Equity and liabilities	ALK Group		
	Sept. 30, 2009	Dec. 31, 2008	Sept. 30, 2008
Amounts in DKKm			
<b>Equity</b>			
Share capital	101	101	101
Other reserves	1,781	1,761	1,760
<b>Total equity</b>	<b>1,882</b>	<b>1,862</b>	<b>1,861</b>
<b>Liabilities</b>			
<b>Non-current liabilities</b>			
Mortgage debt	28	29	44
Bank loans and financial loans	13	15	16
Pensions and similar liabilities	75	73	76
Other provisions	142	142	147
Other payables	2	8	11
	<b>260</b>	<b>267</b>	<b>294</b>
<b>Current liabilities</b>			
Mortgage debt	1	1	2
Bank loans and financial loans	4	4	4
Trade payables	97	128	76
Income taxes	53	31	62
Other provisions	-	-	4
Other payables	272	245	270
Deferred income	9	-	-
	<b>436</b>	<b>409</b>	<b>418</b>
<b>Total liabilities</b>	<b>696</b>	<b>676</b>	<b>712</b>
<b>Total equity and liabilities</b>	<b>2,578</b>	<b>2,538</b>	<b>2,573</b>

## EQUITY (unaudited)

Amounts in DKKm	Other reserves					Total equity
	Share capital	Hedges of future transactions	Currency translation adjustment	Retained earnings	Total other reserves	
<b>Equity at January 1, 2009</b>	<b>101</b>	<b>-</b>	<b>(28)</b>	<b>1,789</b>	<b>1,761</b>	<b>1,862</b>
<b>Total comprehensive income</b>	<b>-</b>	<b>(1)</b>	<b>(17)</b>	<b>82</b>	<b>64</b>	<b>64</b>
Share-based payments	-	-	-	6	6	6
Dividend paid	-	-	-	(50)	(50)	(50)
<b>Other transactions</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(44)</b>	<b>(44)</b>	<b>(44)</b>
<b>Equity at September 30, 2009</b>	<b>101</b>	<b>(1)</b>	<b>(45)</b>	<b>1,827</b>	<b>1,781</b>	<b>1,882</b>
<b>Equity at January 1, 2008</b>	<b>101</b>	<b>(3)</b>	<b>(22)</b>	<b>2,036</b>	<b>2,011</b>	<b>2,112</b>
<b>Total comprehensive income</b>	<b>-</b>	<b>7</b>	<b>3</b>	<b>63</b>	<b>73</b>	<b>73</b>
Share-based payments	-	-	-	6	6	6
Dividend paid	-	-	-	(330)	(330)	(330)
<b>Other transactions</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(324)</b>	<b>(324)</b>	<b>(324)</b>
<b>Equity at September 30, 2008</b>	<b>101</b>	<b>4</b>	<b>(19)</b>	<b>1,775</b>	<b>1,760</b>	<b>1,861</b>

## NOTES (unaudited)

## 1 ACCOUNTING POLICIES

The interim report for the period January 1 to September 30, 2009 is presented in accordance with IAS 34 "Interim financial reporting" as adopted by the EU and additional Danish disclosure requirements for interim reports of listed companies. The additional Danish disclosure requirements are defined in the Danish Executive Order on Interim Reports issued under the Danish Financial Statements Act.

In 2009, ALK implemented an amendment to IAS 1: *Presentation of financial statements – Comprehensive income, etc.*, IFRS 8: *Operating segments* and IAS 23: *Borrowing costs*.

As a result of the amendment to IAS 1, the presentation of comprehensive income for the period is placed immediately after the income statement as opposed to previously when it was part of the statement of changes in equity. The implementation of IFRS 8 did not result in any changes, as the ALK Group's activities remain solely within one operating segment: Allergy treatment. The implementation of IAS 23 did not affect the recognition and measurement of assets of own construction in 2009. Otherwise, the accounting policies are unchanged from the accounting policies applied in the Annual Report 2008.

Reference is made to the Annual Report 2008 for a more detailed description of the accounting policies.

## 2 REVENUE

ALK Group			ALK Group	
Q3 2008	Q3 2009	Amounts in DKKm	9M 2009	9M 2008
		<b>Revenue by product line</b>		
216	230	SCIT	666	611
111	118	SLIT - droplets	401	380
19	29	SLIT - tablets (GRAZAX®)	94	63
346	377	<b>Vaccines</b>	1,161	1,054
91	89	Other products	232	254
437	466	<b>Total</b>	1,393	1,308
		<b>Revenue by market</b>		
108	109	Northern Europe	294	315
181	196	Central Europe	563	515
104	111	Southern Europe	382	351
44	50	Other markets	154	127
437	466	<b>Total</b>	1,393	1,308

Q3 2009			9M 2009	
Growth reported	Organic growth		Organic growth	Growth reported
		<b>Growth in revenue by product line</b>		
6%	7%	SCIT	8%	9%
6%	7%	SLIT - droplets	6%	6%
53%	62%	SLIT - tablets (GRAZAX®)	53%	49%
9%	10%	<b>Vaccines</b>	10%	10%
-2%	-1%	Other products	-5%	-9%
7%	8%	<b>Total</b>	7%	6%
		<b>Growth in revenue by market</b>		
1%	8%	Northern Europe	0%	-7%
8%	8%	Central Europe	9%	9%
7%	7%	Southern Europe	9%	9%
14%	9%	Other markets	10%	21%
7%	8%	<b>Total</b>	7%	6%

## NOTES (unaudited)

## 3 OTHER OPERATING INCOME AND OTHER OPERATING EXPENSES

Other operating income and other operating expenses relate to income and expenses of secondary nature relative to ALK's main activities. The item includes income and expenses of net DKKm 25 (2008: DKKm 28) in relation to an agreement with Schering-Plough on a strategic alliance to develop and commercialize ALK's tablet-based allergy vaccines against grass pollen allergy (GRAZAX<sup>®</sup>), house dust mite allergy and ragweed allergy for the North American markets.

## 4 KEY CURRENCIES AND CURRENCY SENSITIVITY

Average exchange rates per unit of foreign currency		
Amounts in DKK	9M 2009	9M 2008
USD	5.45	4.89
GBP	8.40	9.51

Sensitivity in the event of a 10% increase in exchange rates (full year effect)		
Amounts in DKKm	Revenue	EBIT
USD	approx. +15	approx. -15
GBP	approx. +15	approx. +10

The sensitivities are estimated on the basis of current exchange rates.

## DEFINITIONS

<b>Invested capital</b>	<i>Intangible assets, tangible assets, inventories and current receivables reduced by liabilities except for mortgage debt, bank loans and financial loans</i>
<b>Gross margin – %</b>	<i>Gross profit x 100 / Revenue</i>
<b>EBIT margin – %</b>	<i>Operating profit x 100 / Revenue</i>
<b>Net asset value per share</b>	<i>Equity at end of period / Number of shares at end of period</i>
<b>Earnings per share (EPS)</b>	<i>Net profit/(loss) / Average number of outstanding shares</i>
<b>Diluted earnings per share (DEPS)</b>	<i>Net profit/(loss) / Diluted average number of outstanding shares</i>
<b>Cash flow per share (CFPS)</b>	<i>Cash flow from operating activities / Average number of outstanding shares</i>
<b>Markets</b>	<i>Geographical markets: o Northern Europe comprises the Nordic region, the UK and the Netherlands o Central Europe comprises Germany, Austria, Switzerland and Poland o Southern Europe comprises Spain, Italy and France o Other markets comprise the USA, Canada, China and rest of world</i>

Key figures are calculated in accordance with "Recommendations and Ratios 2005" issued by the Danish Society of Financial Analysts.